About

Science

Pipeline

Investor Information

Contact Us

Investor Information

Investor Information

Press Releases

Aug 21, 2018 7:00 AM EDT Can-Fite Announces Enrollment of First Patient in its Comfort™ Phase III Trial of Piclidenoson in Psoriasis
Aug 7, 2018 9:14 AM EDT Can-Fite Receives from CMS Medical Venture Investment Limited $2,000,000 Upfront Payment as Part of Development, Registration and Marketing Agreement for Piclidenoson and Namodenoson in China
Aug 6, 2018 5:54 AM EDT Can-Fite Signs Multi-Million Dollar Development and Distribution Agreement for Piclidenoson and Namodenoson in China with CMS Medical
Jul 17, 2018 7:00 AM EDT Can-Fite Granted Australian and Chinese Patents for Erectile Dysfunction Drug
Jul 2, 2018 7:00 AM EDT Drugs with Mechanism of Action Utilized by Namodenoson Are Recommended by Leading U.S. Researchers to Be Developed to Combat Liver Cancer
Jun 19, 2018 7:00 AM EDT Can-Fite Updates on Status of Phase II Advanced Liver Cancer Trial
Jun 11, 2018 7:00 AM EDT Can-Fite Reports on New Pre-Clinical Developments with Its NASH Drug Namodenoson
Jun 1, 2018 7:00 AM EDT Can-Fite Reports First Quarter 2018 Financial Results and Provides Clinical Update
Apr 25, 2018 7:00 AM EDT Can-Fite's Piclidenoson Mechanism of Action in Psoriasis Published in 'Journal of Immunology Research'
Apr 9, 2018 7:00 AM EDT Can-Fite to Present the Anti-Inflammatory and Anti-Fibrogenic Effects of Namodenoson in NAFLD/NASH Pre-clinical Studies at the 2018 International Liver Congress of the European Association for the Study of the Liver (EASL)

Show All